Manitoba pharmacists will soon have ability to prescribe birth control, HIV medications
Pharmacists in Manitoba will soon be able to prescribe birth control, the province's health minister revealed this week in an announcement that came as a pleasant surprise to the industry.
Health Minister Uzoma Asagwara told the legislature Wednesday that granting pharmacists the means to assess and prescribe contraceptives is a "very reasonable expansion of scope for pharmacists in Manitoba."
The minister added in an interview the government is moving "very quickly" on the changes, which will take effect "in the coming days and weeks."
"We're trying to get it out the door as quickly as we can for pharmacists across the province who have been asking for this for years," they said.
Pharmacists will also be able to prescribe HIV medications beginning this summer, a government official said.
Manitoba, Ontario and the three territories are the only places in Canada that do not currently allow pharmacists to prescribe birth control.
Emergency contraceptives, such as the Plan B pill, are currently available without a prescription from pharmacies.
"Right now in Manitoba, pharmacists do not have the ability to practise at their full scope, the way that they should," said Asagwara, who pledged "to go even further" in granting pharmacists more prescribing authority.
Members of the industry association Pharmacists Manitoba were in the legislature to watch question period Wednesday, after they were informed that Liberal MLA Cindy Lamoureux would ask questions about pharmacists' scope of practice.
In her first question, Lamoureux asked if the government planned to "enable and empower pharmacists who directly assess and prescribe contraception."
The question prompted a sometimes rare occurrence in question period: a direct answer to the question posed.
"The short answer to that question, for the member of Tyndall Park, is yes," Asagwara said.
Britt Kural, the pharmacy practice adviser with Pharmacists Manitoba, said she was "pleasantly surprised" by the response.
"We had no idea that there was going to be something right around the corner," said Kural.
The pharmacist said she believes she and her colleagues will be able to prescribe products like daily oral birth control pills, hormonal injections and IUDs, but the province hasn't provided those details yet.
Currently, a patient must go to a doctor's office or a nurse practitioner to receive a prescription for birth control, and must then visit a pharmacist to pick it up.
This regulatory change will save patients from seeing a doctor or nurse practitioner.
"Quite often pharmacists are a first point of care for many people in Manitoba, because they don't have access to a primary care physician or a nurse practitioner, especially in rural and remote communities," Kural said.
She couldn't estimate what kind of uptake pharmacists will see, but said her profession is eager to help.
Women's Health Clinic executive director Kemlin Nembhard said any step toward making prescription birth control more accessible is worth celebrating.
The change will make contraceptives easier to access for people without a family doctor, or for young people who worry about their parents finding out, she said.
While Manitoba's NDP government has been offering free prescription birth control since October of last year, Nembhard said some hurdles to accessing these contraceptives persist, such as the requirement to have a health card. It's one of the reasons the clinic runs a free birth control program, funded entirely through donations.
"It would be great for us to get funding through the province to support that program," Nembhard said.
Kural said Manitoba's pharmacists would like to further expand their prescribing authority. Some options could include prescriptions to treat the minor ailments pharmacists are already assessing, such as strep throat, ear infections and cold sores, Kural said.
Any such move would require regulatory changes from the province.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 hours ago
- Politico
Is Rubio's PEPFAR claim ‘made up'?
Presented by With Carmen Paun and Robert King Driving the day SHOW ME THE MONEY — Democrats are sparring with Secretary of State Marco Rubio over the President's Emergency Plan for AIDS Relief, the HIV and AIDS program credited with saving millions of lives in poor countries, Carmen, Amanda Friedman and Robert report. President Donald Trump shut down the agency that signed off on most PEPFAR spending and fired staffers who supported it. Democrats say the administration is lying about the state of the program following massive foreign aid cuts led by Elon Musk and his Department of Government Efficiency. Rubio has suggested those concerns are overblown, considering that PEPFAR remains '85 percent operative,' a claim that he made repeatedly in budget testimony before Congress. But neither Rubio nor the State Department will provide a detailed accounting to back up the figure. Dems say: 'It's made up,' Hawaii Sen. Brian Schatz said when asked by POLITICO about the 85 percent figure. 'It's the most successful, bipartisan, highly efficient life-saving thing that the United States has ever done, and Elon Musk went in and trashed it.' Schatz confronted Rubio about the cuts at a Foreign Relations Committee hearing in May, telling him: 'You are required to spend 100 percent of the money.' Rubio's retort: Rubio said the 15 percent cut targeted programs that weren't delivering the services the government was paying for. He pointed to fraud in Namibia and armed conflict in Sudan as reasons for slashed funding, although it isn't clear those instances were related to PEPFAR. Asked repeatedly by POLITICO for more clarity on what the 85 percent figure represents, a State Department spokesperson said that 'PEPFAR-funded programs that deliver HIV care and treatment or prevention of mother to child transmission services are operational for a majority of beneficiaries.' Data collection is ongoing to capture recent updates to programming, the spokesperson also said, adding: 'We expect to have updated figures later this year.' The day after his exchange with Schatz, Rubio told the House Foreign Affairs Committee that he meant 85 percent of PEPFAR's beneficiaries were still getting U.S. assistance. But the goal, he said, was to pass off the work to the countries where the beneficiaries live. 'We're by far the most generous nation on Earth on foreign aid, and will continue to be by far with no other equal, including China, despite all this alarmist stuff,' he said. Big picture: For flummoxed Democrats, the tussle with Rubio indicates a broader problem: How to respond to Trump's budget requests when his administration refuses to spend the money Congress has provided. Trump last month asked Congress to cut PEPFAR's budget for next year by 40 percent. WELCOME TO MONDAY PULSE. I'm Erin Schumaker, POLITICO's National Institutes of Health reporter, filling in today for Kelly. Are you a current or former NIH employee considering a job offer abroad? Shoot me a message! Send your tips, scoops and feedback to eschumaker@ and khooper@ and follow along @erinlschumaker and @Kelhoops. Congress RACE TO FINISH MEGABILL — Senate Republicans could finalize their domestic policy megabill this week, Robert reports, finally tackling Medicaid changes. Republicans are expected to release text for the Medicaid portion of the spending package, which seeks to extend President Donald Trump's tax cuts. The megabill includes changes to Medicaid, like restrictions on eligibility, to help generate more than $700 billion in savings to pay for the tax cuts. Senate Republicans generally agree on adding work requirements, which will mandate some able-bodied beneficiaries complete 80 hours a month of work, job training or another activity. There are exemptions for pregnant women and disabled people, among others. But there are some disagreements surrounding states' ability to levy taxes on hospitals and other providers to pay for their share of Medicaid, which is funded jointly by the federal and state governments. The House version places a moratorium on new state provider taxes but leaves current ones intact. But the question is whether the moratorium will remain intact in the Senate bill, which leadership aims to pass before July 4. Insurance PUSH AGAINST MEDICARE ADVANTAGE CHANGES — A key insurer-backed advocacy group is trying to block Senate Republicans from changing the popular Medicare Advantage program to find savings for their domestic policy megabill, Robert reports. The Better Medicare Alliance, which includes insurers among its members and advocates for Medicare Advantage, is running ads in the Washington Reporter calling for Republicans to protect the program that enables older Americans to buy private insurance plans offering benefits not covered by traditional Medicare, like dental. The group said it will also share polling data with lawmakers that shows older Americans overwhelmingly oppose the changes being discussed. 'Cutting Medicare Advantage, and particularly in-home care, would break a promise to millions of seniors who rely on it,' said Mary Beth Donahue, president and CEO of the Better Medicare Alliance. Last week, Senate Republicans weighed whether to add a bill co-sponsored by Sens. Bill Cassidy (R-La.) and Jeff Merkley (D-Ore.) to the larger package, which seeks to extend President Donald Trump's tax cuts. The legislation, called the No UPCODE Act, clamps down on tools Medicare Advantage plans use to generate higher payments from the federal government. Cassidy pushed back on the attacks from the insurance industry and Democrats who said the legislation cuts benefits. 'We're taking care of patients and we're trying to rescue the program,' he said in a statement. 'To say the No UPCODE Act has bipartisan support is an understatement. This addresses an issue both Republicans and Democrats have called waste, fraud and abuse.' Merkley said in a statement that he still supports the legislation but that it should be considered 'through regular order, not in the context of a partisan bill that will end up leaving 16 million people without healthcare.' The House did consider adding similar language to its bill but eventually backed off. AROUND THE AGENCIES NIH BUDGET TALKS — NIH Director Jay Bhattacharya will testify tomorrow on the agency's budget proposal, which calls for a 40 percent funding cut. The hearing before the Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee comes amid widespread discontent at the NIH. Last month, members of the NIH fellows union walked out of a town hall Bhattacharya held in protest of cuts to programs, layoffs and funding uncertainty. While Congress will ultimately decide how much money the agency gets, and could restrict how it's dispersed, we'll be watching for how Bhattacharya defends: — The indirect cost rate cap. The budget plan proposes capping at 15 percent the rate the NIH pays for administrative and facilities costs to grantees. But lawmakers, including Republicans, have criticized indirect cost caps, which the NIH first tried to impose in February. A federal court blocked that move, and the administration has appealed. Notably, the NIH budget proposal also asks Congress to stop restricting how the NIH sets indirect cost rates. — Downsizing the NIH. The budget plan suggests consolidating the agency's 27 institutes and centers into an eight-institute structure, eliminating the National Institute of Nursing Research, the National Center for Complementary and Integrative Health, the National Institute on Minority Health and Health Disparities and the Fogarty International Center, which promotes collaboration with foreign researchers. — Spending this year's budget. While Tuesday's hearing is about the 2026 budget, Bhattacharya is likely to be questioned about this year's budget, too. During a May 29 meeting with disease advocacy organizations, Bhattacharya promised to fully utilize the NIH's fiscal 2025 budget. But with billions of dollars in grants terminated or delayed since Trump was inaugurated, researchers and NIH staffers worry the 2025 budget won't get spent before the fiscal year ends Sept. 30. WHAT WE'RE READING POLITICO's Juan Perez Jr. reports on how President Donald Trump has universities in the bind the right has long wanted. Reuters' P.J. Huffstutter reports on how the Trump administration's aid cuts are straining food banks in Ohio. The Washington Post's Erin Blakemore reports on new research that could explain why the human brain has such large storage capacity.
Yahoo
4 hours ago
- Yahoo
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX's promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the creation of a Scientific Advisory Board to provide counsel and insight into the development of ModeX's immunology and oncology-focused pipeline featuring potential first-in-class multispecific antibodies and vaccines developed with its proprietary MSTAR platform technology. Aligned with the company's primary areas of focus, the board is comprised of established leaders across complex diseases involving the immune system including cancer, immune-mediated disease, and infectious diseases. The founding members include Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed. Each of these globally recognized researchers brings notable contributions to biomedical research and the translation of therapeutics to impact public health. 'We are excited to welcome to our team four eminent scientists who share our vision of advancing next-generation immune therapies that simultaneously attack multiple targets and help patients overcome devastating diseases,' said Gary Nabel, M.D., Ph.D., President and Chief Executive Officer of ModeX, and Chief Innovation Officer of OPKO. Members of the ModeX Scientific Advisory Board include the following: Rafi Ahmed, Ph.D. - Director of the Emory Vaccine Center and Georgia Research Alliance Eminent Scholar, Emory University School of Medicine. Dr. Ahmed's work in immunology has been highly influential in shaping our understanding of immunological memory to vaccines and T cell exhaustion during chronic viral infection. These findings have led to improved vaccination strategies and to the development of PD-1 directed immunotherapy for cancer. Dr. Ahmed is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. Myron Cohen, M.D. - Professor of Medicine, Microbiology, and Immunology at the University of North Carolina (UNC), Director at the UNC Institute for Global Health and Infectious Diseases, Associate Vice Chancellor for Global Health at UNC, and Associate Director of the UNC Center for AIDS Research. Dr. Cohen's career has focused on the transmission of STDs, including HIV, and strategies for prevention. He was an architect of landmark studies that demonstrated that treatment of HIV prevents its transmission, a catalyst for current global HIV prevention efforts. John Heymach, M.D., Ph.D. - Chair of Thoracic/Head and Neck Medical Oncology and a professor at the University of Texas MD Anderson Cancer Center. He is a co-leader of the Center's Lung Cancer Moon Shot and serves as a Principal Investigator of lung cancer programs funded by the National Cancer Institute, LUNGevity, and the American Association for Cancer Research. His research has led to novel therapeutic approaches for multiple types of lung cancer, and as a clinical investigator, he leads several biomarker-directed clinical trials using targeted and immunotherapy agents. Ronald Levy, M.D. - Professor of Medicine and Co-Director of the Hematologic Malignancies Program at Stanford University. He also serves as Associate Director of Translational Science for the Stanford Cancer Institute. His research has focused on monoclonal antibodies and the study of malignant lymphoma. Dr. Levy was a pioneer in successfully treating cancer with monoclonal antibodies and played a role in the development of rituximab for the treatment of lymphomas. 'Through my research I have witnessed how targeted antibody therapies have transformed the treatment of cancer and profoundly impacted patients' lives globally,' said Dr. Ronald Levy, a Professor of Medicine, and Co-Director of the Hematologic Malignancies Program at Stanford University. 'Multispecific treatments are writing the next chapter by overcoming the limitations of existing antibody treatments and expanding accessibility to many more patients. Alongside the experts joining me on this advisory board, I look forward to helping the ModeX team fulfill this mission.' 'Drs. Heymach, Levy, Cohen, and Ahmed are globally recognized leaders in their respective field. We are grateful for their interest, counsel and support to achieve the full potential of our proprietary multispecific antibody technologies including to revolutionize the treatment landscape for millions of patients,' said Phillip Frost, M.D., Chairman and Chief Executive Officer, and Elias Zerhouni, M.D., Vice Chairman and President, of OPKO. Beyond bispecifics: ModeX's multispecific antibody platformMultispecific therapeutics represent the future of medicine. Many untreatable or complex conditions arise from multiple disease pathways, yet most medicines only act on a single target. ModeX overcomes these challenges by combining natural protein structures to create unique multispecific medicines that can harness the immune system and address the complexity of disease. About ModeX TherapeuticsModeX Therapeutics is the leading clinical-stage biopharmaceutical company developing unique and proprietary multispecific therapeutics. Its MSTAR platform unites the power of multiple biologics in a single molecule to create multispecific antibodies that bind four or more targets with unprecedented versatility and potency to fight complex diseases. Its promising first-in-class immunology pipeline includes candidates against immune diseases, including cancer (both solid and hematologic tumors), immune impairment, as well as several of the world's most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Weston, Massachusetts. For more information, please visit About OPKO Health, is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, visit Cautionary Statement Regarding Forward-Looking StatementsThis press release contains 'forward-looking statements,' as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'could,' 'may,' 'anticipates,' 'believes,' 'should,' 'intends,' 'estimates,' and other words of similar meaning, including whether the benefits of the Scientific Advisory Board will be realized, including whether the Board will effectively aid in the advancement and development of ModeX's immunology and oncology focused pipeline as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, the success of our relationship with our commercial partners, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, and that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. Contacts:InvestorsAlliance Advisors IRYvonne Briggs, 310-691-7100ybriggs@ Voss, 310-691-7100bvoss@ ModeX Media Relationsmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Who can and can't give blood, as NHS calls for donations
The NHS is calling for 200,000 new donors to come forward as it warns of a "challenging" blood supply shortage. Currently only 2% of the population – just under 800,000 people – supports the entire UK blood supply. Since last year, the health service has been on "amber alert" – meaning supplies have dwindled to the point that it may impact patient treatment. Now, experts are warning that things have turned "critical" and are nearing "red alert" status. Here, we take a look at the criteria for donating blood – as well as the most common blood types and how to sign up. According to Give Blood, the general criteria for donating is: That you are aged 17-65 You're generally fit and healthy You weigh between 7 stone 12 lbs and 25 stone You have suitable veins You meet all donor eligibility You cannot donate blood if: You've got some heart conditions, such as heart palpitations, abnormal heartbeat – or if you've had a heart attack, stroke, a heart bypass or you were born with a congenital heart defect You have tested positive for HIV You've had an organ transplant You have had most types of cancer You have received blood, platelets, plasma or any other blood products after 1 January 1980 You carry hepatitis B or C You've injected non-prescription drugs – including body-building and injectable tanning agents You may be asked to wait to donate blood if: You've given blood too recently – Providing you're otherwise eligible, men can give blood every 12 weeks and women can give blood every 16 weeks. You are pregnant or you've had a baby in the past six months – You will not be permitted to give blood while pregnant. Nor can you donate blood if you had a blood transfusion during your pregnancy or delivery. If you are trying to conceive it is not recommended, as you'll require all iron stores if/when you do fall pregnant. Once you have passed the six-month post-delivery mark, you may be able to donate blood. You've recently got a tattoo or a piercing – Although most tattoo and piercing parlours offer safe services, the introduction of a foreign object to the body still carries risk, and so to protect the recipient of the blood, donors must wait for four months after having a tattoo of piercing before they can give blood. This includes microblading or semi-permanent make-up, as well as acupuncture. You feel ill at the time of donation – It's common for donors to feel faint or anxious before, during and after the procedure, but if you are feeling unwell you must flag ahead of time, as it is important that you do not carry any infection at the time of donating. In order to donate, you must be healed and recovered from an infection for at least 14 days prior. You're undergoing medical assessment – Similarly, if you are undergoing medical tests and assessments, you may have to wait before you donate blood. You travel to and from certain countries outside of the UK – You can check whether your travels impact your eligibility to give blood here. You've had a new sexual partner in the past three months – Regardless of gender, if you've had anal sex with a new partner in the past three months, you might not be able to give blood. Similarly, if you finished taking Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis (PEP) in the last three months, you'll have to wait. You've had sexual contact with a partner who is – HIV positive, HTLV positive, carries hepatitis B or C, syphilis positive, has injected non-prescribed drugs, has received money or drugs for sex. You will need to wait at least three months. If you have any health conditions or you're on medication, you can check your eligibility at the NHS Give Blood website here. O positive is the most common blood type, accounting for roughly 35% of donors. It's followed by blood type A positive, with around 30% of donors falling into this category. The rarest, meanwhile, is AB negative, with just 1% of donors falling into this category. If you would like to sign up to donate blood or plasma, you can do so at the Give Blood website here. You can also call them on 0300 123 23 23. The NHS site also outlines which donor centres have availability today – you can check here. Some sites also welcome walk-ins. You can find your nearest centre here. Read more about health 10 foods that may reduce your risk of developing dementia (Yahoo Life UK 7-min read) 7 myths and truths about inducing labour, from dancing to spicy food (Yahoo Life UK 6-min read) Are nicotine pouches as bad as vaping and smoking? (Yahoo life UK. 6-min read)
